Pharmacovigilance and Adverse Drug Reactions reporting:

CHF 41.45
Auf Lager
SKU
SJQ9B9MFNBG
Stock 1 Verfügbar
Geliefert zwischen Mo., 26.01.2026 und Di., 27.01.2026

Details

Adverse drug reactions (ADRs) are considered one of the major factors causes mortality and morbidity. The main purpose of Pharmacovigilance (PV) is to identify the drug safety. The aims of this study are to evaluate the health care professional's knowledge, Attitude and Practice (KAP) toward PV and ADRs reporting and to determine the factors that may encourage and discourage health care professionals to report ADRs in Al-Qassim hospitals in Saudi Arabia. All healthcare providers have roles to play in maintaining a balance between a medicine's benefits and risks. Once a drug is available to the public, making a determination about its safety is the shared responsibility of all who are part of the prescribing process

Autorentext

Salwa Selim Abougalambou 19/3/2011 awarded the doctor of philosophy degree of clinical pharmacy from Universiti Sains Malaysia.17/8/2008 awarded in master's degree of clinical pharmacy from Universiti Sains Malaysia. Khawla Alhammad 28/1/2018 awarded pharm D degree from Qassim University.

Weitere Informationen

  • Allgemeine Informationen
    • GTIN 09783330034969
    • Sprache Englisch
    • Größe H220mm x B150mm
    • Jahr 2017
    • EAN 9783330034969
    • Format Kartonierter Einband
    • ISBN 978-3-330-03496-9
    • Titel Pharmacovigilance and Adverse Drug Reactions reporting:
    • Autor Salwa Abougalambou , Ahood Meshal Al-Mutairi
    • Untertitel Knowledge, attitude and practice among healthcare professionals in Al-Qassim hospitals
    • Herausgeber LAP Lambert Academic Publishing
    • Anzahl Seiten 60
    • Genre Medical Books

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.
Made with ♥ in Switzerland | ©2025 Avento by Gametime AG
Gametime AG | Hohlstrasse 216 | 8004 Zürich | Schweiz | UID: CHE-112.967.470